Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients

Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients

Abstract Background Camrelizumab (CAM) combined with apatinib plus chemotherapy as a first-line treatment shows good efficacy in advanced or metastatic esophageal squamous cell carcinoma (ESCC) patients. This study aimed to explore the potential of CAM combined with apatinib plus irinotecan (IRT) as...

Full description

Saved in:
Bibliographic Details
Main Authors: Shusheng Wu, Huiqin Luo, Wenju Chen, Xudong Liu, Huimin Li, Mengge Li, Lihong Ke, Jiayu Niu, Bing Hu, Huijun Xu, Gang Wang, Ying Yan, Lulu Cao, Xiaoxiu Hu, Chenghui Li, Yifu He
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Cancer
Subjects:
Advanced or metastatic esophageal squamous cell carcinoma
Camrelizumab
Apatinib
Second-line treatment
Predictive models
Online Access:https://doi.org/10.1186/s12885-025-14207-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14207-8

Similar Items